Media Release
EditForce raises 870 million JPY
Fukuoka, Japan, 1 March, 2019 – EditForce Inc. (“EditForce”) has announced that it has raised
870 million yen (7.84 million US dollars) by March 1, 2019, from six new and existing investors
in the Series B2 round, as described below.
EditForce, a venture company with a unique DNA/RNA editing technology, was founded byKISCO LTD. and Takahiro Nakamura, PhD, Associate Professor, Kyusyu University in 2015, andit is supported by The University of Tokyo Edge Capital Co., Ltd. (UTEC) and QB capital, LLC.
It has been developing its independent pentatricopeptide repeat (PPR) protein platform technology.
The technology has a distinct feature that enables the editing of not only DNA but also RNA,highlighting its difference compared to other technologies, and is thus expected to be applied toa wide range of fields. The platform technology has also different mechanism to work and isolated
IP from other existing DNA editing technologies. EditForce decided to focus on thepharmaceutical field since 2017 and is making efforts to develop PPR to be applied in the field ofnovel pharmaceutical development through business alliances with multiple pharmaceuticalcompanies.
In this round, in addition to KISCO LTD., which has supported EditForce since its foundation,UTEC, a lead investor in the Series B round and QB Capital, LLC, which has supported EditForceas a venture company from Kyushu University, EditForce has raised funds from Newton
Biocapital, ITOCHU Technology Ventures, Inc., Japan Science and Technology Agency (JST),and K4 Ventures Good Kaisha. By taking full advantage of the broad networks and deep expertise
owned by these corporations, it endeavors to successfully apply the unique PPR technologyworldwide in pharmaceuticals, agriculture, and chemistry fields.
Dr. Takahiro Nakamura, President of EditForce commented, “I believe investments bycorporations with various backgrounds and deep expertise in EditForce clearly show that the PPR
protein platform, the fundamental technology of our company, is highly regarded as a valuable
tool in various fields. In order to develop the PPR protein platform as a globally recognized andbroadly used technology from Japan, we must expend our utmost efforts into research anddevelopment of the technology while also making “products” based on the technology as soon as
possible. In our medium-term plan, we focus on the area of pharmaceuticals with increasing
demand in the market.”Dr. Toshiyuki Mori, Investment Partner of Newton Biocapital, a co-lead investor in theSeries B2 round, commented, “As Newton Biocapital's first investment project in Japan,
we are extremely pleased to have invested in EditForce, which has unique anddistinguished DNA/RNA editing technology. By bringing experienced members in drug
R&D and global business development experts, we look forward to contribute to expand
the business of EditForceMr. Koji Abe, Senior Vice President at ITOCHU Technology Ventures, Inc, another co-lead
investor in this round, commented, “EditForce’s unique DNA/RNA editing technology is
indispensable core tool for gene therapy. PPR platform also has a huge potential to be applied inother bio-related industries in addition to pharmaceuticals in the future. We are very excited tobe able to support the company to grow as a key player in the industry and deliver significant
benefits to the global society.”

Investors:-The University of Tokyo Edge Capital Co., Ltd. (UTEC)-QB Capital, LLC-Japan Science and Technology Agency (JST)-Newton Biocapital-ITOCHU Technology Ventures, Inc.
-K4 Ventures Godo Kaisha (The Kansai Electric Power Group)About EditForce:
It is a venture company that is developing a PPR protein platform technology as the DNA/RNA
editing tool.
Headquarters: Fukuoka Tenjin Fukoku Seimei Bldg., 4th Fl.
1-9-17 Tenjin, Chuo-ku, Fukuoka-shi, Fukuoka 810-0001, Japan
Phone +81-92-741-8484
Capital:753, 925, 350 JPY as of March 1, 2019

President:

Takahiro Nakamura

Boardof Takashi Ono (Board Director, COO)

Directors:Takekazu Kishimoto (KISCO LTD. President)
Teruyuki Fukuda (KISCO LTD. Executive Officer)
Atsushi Usami (The University of Tokyo Edge Capital Co., Ltd, Partner)

Auditand Yasunobu Akimitsu (KISCO LTD.

Supervisory
Board:

Finance and Accounting Depart, General Manager)
Tomotaka Goji (The University of Tokyo Edge Capital Co., Ltd,Managing Partner and President)

About PPR platform technology:
PPR is a protein that was discovered in plants, which regulates the gene expression by binding
RNA or DNA in a sequence-specific manner. PPR proteins are also found in humans and yeasts,
and they have similar functions to those of plants. Dr. Takahiro Nakamura (associate professor,Kyushu University, and president of EditForce) and Dr. Yusuke Yagi focused on the PPR proteinsand elucidated the recognition mode of RNA/DNA by PPR proteins. This elucidation paves theway to a new technology for the rational design of artificial PPR proteins targeted to specific
RNA/DNA sequences. Versatile DNA/RNA editing tools can be created by integrating the PPR
protein with various enzymes.
About KISCO LTD.:Tokyo, Japan; Takekazu Kishimoto, President
Since its founding in 1921, KISCO LTD. is a specialized trading and business developing
company that offering solutions meet customers' needs with a wide range of fields such as
chemicals, synthetic resins, electronics materials, packaging materials and biotechnology.
We have trading offices and manufacturing bases in Japan, China, Asia, Americas and Europe,
aiming for existence that plays a role as a bridge between advanced materials and customers,
and has expanded the scope of our activity areas.
For more information on KISCO Corporation, please visit our web site.

www.kisco-net.com

About The University of Tokyo Edge Capital (UTEC):Tokyo, Japan; Tomotaka Goji, Managing Partner and President
Since its inception in 2004, The University of Tokyo Edge Capital (UTEC) has conducted venture
capital investments pioneering frontiers to solve global issues of humankind, by bringing capital, talentand knowledge, around science and technology. With our latest fund UTEC 4 Limited Partnershipfounded with the commitment of approx. JPY 24.2 billion in April 2018, we have founded four funds
totaling approx. JPY 54.3 billion. We have invested in approx. 100 start-ups, 10 of which went public
and 10 were acquired in M&A transactions.
About QB Capital, LLC:

Fukuoka, Japan; Tsuyoshi Sakamoto, Managing Partner, Takashi Hondo, Managing Partner
QB Capital, LLC manages the first “industry-academia collaboration” fund established in Kyushu area.
QB Capital, LLC invests in research seeds and seed- to early-stage ventures, based on research seeds
from universities mainly in Kyushu area. Furthermore, QB Capital, LLC supports the establishmentof these venture companies. QB Capital, LLC tackles the development of an innovative industry inKyushu area and its use in society, by providing “seamless hands-on” support from beginning togrowing-stage of these companies.

About Japan Science and Technology Agency (JST):
Saitama, Japan; Michinari Hamaguchi, President
JST is an organization that leads Japan’s science and technology (S&T) development as an innovation
navigator. JST aim to contribute to the lives of people and the achievement of a sustainable society bypromoting S&T for the purpose of opening up opportunities in innovation. Since its foundation, JST’s
many outstanding achievements accomplished in collaboration with the government, universities, theindustrial sector and public have been earned global recognition. This is the investment program"SUCCESS" for start-ups putting JST-funded R&Ds into practical application.
www.jst.go.jp/EN/index.html

About Newton Biocapital:
Brussels, Belgium; Alain Parthoens, Managing Partner
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech
and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention andtreatment of chronic diseases. The fund's approach as lead investor is to support promising start-up
projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and tocreate investor value. The leadership team consists of specialists with long-standing management andinvestor experience who coach bio-entrepreneurs through the development stages of their projects.

Newton Biocapital's mission is to generate substantial financial and societal value by providing
innovative, breakthrough, and affordable solutions to patients

About ITOCHU Technology Ventures:Tokyo, Japan; Shinzo Nakano, President & CEO/Partner
ITOCHU Technology Ventures, Inc. (ITV) has been engaged in investments in venturecompanies as well as assisting them with solution to carry out its primary mission of fostering
innovative technology venture companies to become a part of the de fact standard in the nextgeneration. Since its establishment in 2000, ITV has been launching four consecutive venture
funds and investing more than 150 companies. ITV’s investment areas include ICT, finance,infrastructure and energy, agriculture, healthcare and medicine, education, social services forthe consumer sector. With its focus on Japan, ITV also invests in potentially prominent foreigncompanies that create advanced and innovative services or technologies.
About K4 Ventures (The Kansai Electric Power Group):
Osaka, Japan; Takashi Morimoto, Chief Executive Officer
K4 Ventures Good Kaisha (K4 Ventures) is a corporate venture capital firm of The Kansai Electric PowerGroup Company. K4 Ventures invests in venture companies that (1) have potential to grow throughcollaboration belong to the energy-related industry, telecommunications industry, and real estate andsocial life industry, or (2) have innovative technologies/visions to provide solutions for customers orworld-wide issues, beyond the short-term collaboration. K4 Ventures supports the growth ofoutstanding venture companies as their partner and promotes collaborations among companies toobtain a synergistic effect. The mission of K4 Ventures is to provide fast, innovative solutions forenergy, environmental, and food-supply issues.

Contact:
EditForce Inc.
Administration Department
Tel:+81-92-802-4935
Fax:+81-92-802-4934
soumu@editforce.jp
Att. Ms. Kawano